Loading...
Market
What will be the status of Emergent BioSolutions' commercial readiness for Ebanga™ by December 31, 2024?
2
Resolution / Starting Odds
Fully ready • 25%
Partially ready • 25%
Not ready • 25%
Unknown/Other • 25%
Official announcements from Emergent BioSolutions or BARDA
Story
Emergent BioSolutions Secures $41.9 Million BARDA Contract Option for Ebola Treatment Development
Sep 13, 2024, 10:48 AM
Emergent BioSolutions has been awarded a research and development option valued at $41.9 million to further the development and scale-up of its monoclonal antibody treatment, Ebanga™, for Ebola virus infection. The BARDA contract option will cover steps such as scale-up process validation, commercial readiness, and post-licensure commitments, including technology transfer and submission of a supplemental Biologics License Application (BLA). This funding aims to enhance the advanced development and procurement of Ebanga™ treatment.
View original story
Similar markets
Full approval • 25%
Emergency use authorization • 25%
Conditional approval • 25%
No approval • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Approved • 25%
Rejected • 25%
Request for more data • 25%
Other • 25%
High efficacy • 25%
Moderate efficacy • 25%
Low efficacy • 25%
No significant efficacy • 25%
Yes • 50%
No • 50%
Partnership with another company • 25%
Focus on different vaccine candidates • 25%
Continue with current strategy • 25%
Other strategic response • 25%
Yes • 50%
No • 50%
